Europe’s Hormone Specialists Sound the Alarm as Burnout and Waiting Times Soar

Europe’s endocrine community has issued an unprecedented warning about the state of hormone healthcare across the continent, launching a formal call for urgent policy action at a moment when demand for specialist care is rising faster than the workforce can possibly absorb. The European Society of Endocrinology has published the Prague Declaration together with a white paper titled Endocrine Workforce 2026: Recommendations for a Healthier Endocrine Future, a document containing 29 distinct recommendations built on the most comprehensive assessment of the continent’s endocrine workforce ever conducted. The initiative arrives at a time when obesity, diabetes and other hormone-related disorders are placing escalating pressure on health systems already operating near their limits, and when the specialists trained to manage those conditions are reporting exhaustion, stalled careers and diminishing time for the research that drives medical progress.

The evidence base behind the Declaration is unusually robust for a workforce study. ESE’s State of Endocrinology surveys drew responses from approximately 2,400 healthcare professionals and researchers across Europe, including more than 250 specialist nurses, and gathered the perspectives of 36 national endocrine societies. This scale matters because workforce planning in medicine has historically relied on fragmented national data, making it difficult to see continental trends or to compare the situation in one country with another. By aggregating responses at this level, the surveys provide the first truly panoramic view of how many endocrine specialists Europe has, what conditions they work under, and whether the pipeline of future expertise is sufficient to meet projected demand. The answer, according to the data, is that it is not.

Among the most striking findings is the length of time patients must wait to see a specialist. More than a quarter of endocrine professionals surveyed reported that new patients at their services wait upwards of 90 days for an appointment. In endocrine medicine, such delays are not merely inconvenient. Conditions such as suspected adrenal insufficiency, thyroid disorders, pituitary tumours and severe metabolic disease can progress substantially during months of waiting, and some, like adrenal crisis in undiagnosed primary adrenal insufficiency, can be life-threatening. Delayed diagnosis also multiplies downstream costs, because advanced disease is more expensive to treat than early disease. Most national societies responding to the surveys expect the gap between demand and capacity to widen further, suggesting that the current waiting-time figures represent a floor rather than a ceiling.

The surveys also document a workforce under significant psychological strain. Stress and burnout are reported as common across the profession, with the burden falling particularly heavily on younger endocrinologists at the start of their careers. More than a third of early-career professionals said they are considering leaving their jobs within the next five years. That figure should alarm policymakers for a straightforward arithmetic reason: early-career specialists represent the future supply of expertise, and if a large fraction of that cohort exits the profession, the workforce cannot replenish itself fast enough to replace both those leavers and the senior clinicians approaching retirement. Burnout in medicine is well documented to correlate with reduced quality of care, higher error rates and increased turnover, creating a feedback loop in which understaffing drives exhaustion, which drives further attrition, which deepens the original understaffing.

Research capacity is suffering alongside clinical capacity. Four in ten respondents reported that they do not have enough time to contribute to research that would improve patient care. This is a problem with long time horizons, because endocrinology research underpins advances in diabetes management, obesity treatment, thyroid cancer therapy, reproductive medicine and rare disease diagnosis. When clinicians cannot participate in research, clinical trials recruit more slowly, translational findings take longer to reach the bedside, and the specialty’s evidence base stagnates. The Declaration frames protected research time and dedicated funding not as a luxury but as a critical investment in future healthcare, arguing that the skills and knowledge generated today determine the treatment options available to patients a decade from now.

Wiebke Arlt, President of the European Society of Endocrinology, framed the crisis in terms of the broader health challenges facing the continent. Europe’s endocrine workforce, she noted, bears the brunt of many of the biggest and most costly health problems of our time, and as obesity, diabetes and other hormone-related diseases affect more people, there must be enough specialist expertise to provide timely, high-quality care. Her point connects endocrinology directly to the economics of chronic disease. Diabetes alone affects tens of millions of Europeans and consumes a substantial share of health budgets, and obesity rates continue to climb in nearly every member state. Every one of those patients ultimately depends on endocrine expertise somewhere in their care pathway, whether for diagnosis, for management of complications or for access to newer pharmacological therapies that have transformed the field in recent years.

Jérôme Bertherat, Chair of the ESE Policy and Advocacy Committee, emphasised that the Declaration is grounded in data rather than anecdote. For the first time, he said, robust survey data show what needs to change, and through the Prague Declaration the society is asking European institutions, national governments, healthcare organisations and medical societies to act on the findings and ensure a resilient and future-proof endocrine workforce. The distinction between advocacy based on impression and advocacy based on systematic survey evidence is important in Brussels, where competing claims on health policy attention are numerous. A documented waiting-time statistic or an attrition figure carries weight in budget negotiations that a general warning about workforce shortages does not.

The 29 recommendations are organised around five key areas. The first calls for more proactive and detailed workforce planning to meet future healthcare needs in both prevalent endocrine and metabolic diseases and complex rare diseases, acknowledging that the specialty spans everything from common diabetes care to ultra-rare adrenal and pituitary conditions. The second addresses the demand-capacity gap directly, promoting prevention, early detection, shared care protocols and new working methods, including artificial intelligence, remote disease monitoring and future technologies, to alleviate the burden of providing increasingly costly and specialised care. The third focuses on working conditions, wellbeing and career support, urging workplace policies that enable flexible careers and ensure early-career professionals feel sufficiently supported. The fourth protects time and funding for research, and the fifth supports fair and sustainable workforce mobility through standardised education and training across European countries and beyond, recognising that free movement of specialists only benefits all parties if qualifications are comparable across borders.

The emphasis on prevention deserves particular attention because it reframes the workforce crisis as a system-wide problem rather than a specialty-specific one. The Declaration notes that better endocrine care can reduce pressures in other specialties, including oncology and cardiology, since endocrine disorders intersect with cancer risk, cardiovascular disease and metabolic dysfunction in ways that are increasingly well understood. Hormonal health, in other words, is not an isolated domain but a foundation on which much of modern medicine rests. An adequately staffed endocrine service that catches thyroid disease early, manages diabetes intensively and identifies metabolic syndrome before it progresses prevents hospitalisations, procedures and drug costs elsewhere in the system. Supporting the endocrine workforce, the Declaration argues, is therefore a strategic investment in Europe’s future health rather than a narrow plea from one professional community.

Whether the Declaration translates into policy will depend on the response of the institutions it addresses. The document provides European and national decision-makers with a clear menu of actions, from workforce planning frameworks to training standardisation to technology adoption, each anchored in survey evidence. What the data make unmistakable is that the status quo is deteriorating: waiting times already exceed 90 days for many new patients, a substantial share of the next generation of specialists is contemplating departure, and four in ten clinicians lack time for research. Hormones regulate growth, metabolism, reproduction and stress, and the physicians and scientists who manage those systems are telling Europe, in the largest survey of its kind, that their capacity to keep doing so is eroding. The Prague Declaration is the profession’s formal request that someone in a position to act start listening before the gap between what patients need and what the workforce can deliver becomes unbridgeable.

Subject of Research: Endocrine workforce shortages and policy recommendations in Europe

Article Title: Europe’s endocrine community calls for urgent policy action as growing demand puts hormone health workforce under pressure

Article References: Europe’s endocrine community calls for urgent policy action as growing demand puts hormone health workforce under pressure. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: endocrinology, workforce shortage, Prague Declaration, European Society of Endocrinology, burnout, diabetes, obesity, health policy, patient waiting times, medical research, workforce planning, hormone health